Krebs Biochemicals & Industries Fair Value
Krebs Biochemicals & Industries (KREBSBIO) average fair value is ₹48.06 across 1 valuation models — Price-to-Sales Valuation, vs a current market price of ₹57.31 (-16.14%), fair value range ₹48.06–₹48.06. Browse KREBSBIO balance sheet details for revenue, profit, balance sheet and cash flow data.
Fair Value Analysis Export
KREBSBIO Fair Value vs Current Price — Valuation Summary
KREBSBIO average fair value, fair value range, price gap and valuation status across 1 models: Price-to-Sales Valuation. Read KREBSBIO ex-dividend dates for the complete payout history and dividend yield track record.
Price-to-Sales Valuation
KREBSBIO Fair Value Analysis — Data Sources & Coverage
Krebs Biochemicals & Industries financial data sources, valuation methods applied and sector benchmarks used. For live price and a broader fundamental view, visit Krebs Biochemicals & Industrie screener.
Available Data Sources: Financial statements, balance sheet data , sector comparisons.
KREBSBIO vs Healthcare Sector Peers — P/E, P/B & Market Cap
Krebs Biochemicals & Industries P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Aurobindo Pharma | AUROPHARMA | 25.88 | 2.53 | ₹96,652 |
| Sat Kartar Life | SATKARTAR | 13.37 | 3.34 | ₹226 |
| Emcure Pharmaceuticals | EMCURE | 36.8 | 7.52 | ₹37,799 |
| Syngene International | SYNGENE | 69.95 | 3.2 | ₹15,307 |
| Divis Laboratories | DIVISLAB | 85.36 | 14.9 | ₹247,470 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.